Patterns of bleeding and plasma concentrations of levonorgestrel, progesterone, estradiol,
LH and FSH were studied in ten volunteers who had a levonorgestrel-releasing IUD inserted …

Human immunodeficiency virus (HIV) infectivity increases as receptor/coreceptor expression
levels increase. We determined peripheral CD4, CCR5, and CXCR4 expression levels in …

The independent as well as interactive effects of chronic (greater than 6 months) oral
contraceptive (OC) use and cigarette smoking on single‐dose (4 mg/kg) theophylline …

A sensitive and reliable radioimmunoassay (RIA) for the measurement of norethindrone
(NET) in serum has been established employing anti-11α,-hydroxynorethindrone 11 …

A levonorgestrel-releasing intrauterine contraceptive device was used by 10 breast-feeding
women beginning 6 weeks after delivery. Two models of IUD were used. One released 10 …

A contraceptive vaginal ring containing levonorgestrel and estradiol was designed in which
the drug is located in a 0.15-mm layer beneath a 0.25-mm overcoat at the ring's surface …

Forty-two healthy women volunteered to have blood samples drawn at 2, 4, 8, 24, 48, and
168 h (7 days) following placement of levonorgestrel-releasing rod (LNG rod) or of …

Abstract Serum norethindrone (NET), FSH, LH, estradiol (E 2) and progesterone (P)
concentrations were measured in 15 women twice weekly for 4 to 6 months following …

IUDs releasing levonorgestrel, 10 μg per day (30 patients) and 30 μg per day (40 patients),
and copper-releasing IUDs (Nova-T)(40 patients) were inserted six weeks after delivery in …

Levonorgestrel, estradiol and progesterone plasma concentrations were measured over four
years of use of a 20 μg/day levonorgestrel-releasing intracervical device (LNG-ICD). The …